Clinical Trials Directory

Trials / Completed

CompletedNCT00332163

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy

A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
95 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPanitumumabAdministered by intravenous infusion
DRUGIrinotecanRecommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
DRUGFOLFIRIChemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
DRUGPre-emptive Skin TreatmentPre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
DRUGReactive Skin TreatmentTreatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)

Timeline

Start date
2006-04-01
Primary completion
2008-01-01
Completion
2008-09-01
First posted
2006-06-01
Last updated
2016-02-23
Results posted
2016-02-23

Source: ClinicalTrials.gov record NCT00332163. Inclusion in this directory is not an endorsement.